上海医药替格瑞洛片获得美国FDA批准上市

Core Viewpoint - Shanghai Pharmaceuticals announced that its subsidiary, Changzhou Pharmaceutical Factory, received final approval from the U.S. Food and Drug Administration (FDA) for the abbreviated new drug application of Ticagrelor tablets, allowing it to be marketed in the U.S. [1] Summary by Relevant Sections - Product Approval - The FDA has granted final approval for the Ticagrelor tablets, which are indicated for patients with acute coronary syndrome [1] - The original drug was launched in the U.S. in 2011 [1] - Target Patient Population - Ticagrelor tablets are used to reduce the incidence of thrombotic cardiovascular events in patients, including those receiving medical therapy and those undergoing percutaneous coronary intervention [1]